Skip to main content

Table 1 Clinical end points in the GOG 229 queue

From: Immunotherapy in endometrial cancer - an evolving therapeutic paradigm

GOG Trial

N

ORR

PFS > 6mo

Median PFS (mo.)

Median OS (mo.)

229 N [7]

28

0 %

11 %

2.1

9.4

229 K [6]

37

9.4 %

22 %

3.3

10.1

229 I [8]

45

18.6 %

30 %

3.3

10.7

229 G* [5]

53

24.5 %

47 %

5.6

16.9

229 F* [4]

49

8.9 %

40 %

2.9

14.6

229 E [3]

56

13.5 %

40.4 %

4.2

10.5

229 J [9]

53

12.5 %

29 %

3.5

12.5

  1. *Significant Grade 3/4 adverse events were encountered on these studies preventing subsequent development of a phase 3 trial; GOG = gynecologic oncology group; ORR = overall response rate; PFS = progression free survival; OS = overall survival
Back to article page

Gynecologic Oncology Research and Practice

ISSN: 2053-6844

Contact us